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INTRODUCTION
The methylenetetrahydrofolate reductase (MTHFR) gene 
has been mapped to chromosomal region 1p36.3. MTHFR 
C677T polymorphism results from a C to T transition at the 
nucleotide position 677 in DNA, leading to the substitution 
of alanine (C) to valine (T) residue at position 226 in the pro-
tein; this results in a decreased basal activity of the enzyme 
by 50% (1). Numerous studies have shown the association 
between homozygous genotype MTHFR 677TT and hyperho-
mocysteinemia. Due to its multiple roles in different cellular 
pathways, the amino acid homocysteine is a unique candidate 
for the study of different cardiometabolic and age-related 
pathological conditions, namely atherosclerosis, obesity, 
diabetes mellitus and the metabolic syndrome (1,2) as well 
as dementia and epilepsy (3,4). The role of homocysteine in 
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predicting risk for atherothrombotic vascular disease has been 
evaluated in several observational studies in a large number 
of patients. Hence hyperhomocysteinemia is considered the 
“cholesterol of nineties” due to the impact on early athero-
sclerosis; it is established from a large body of studies than 
even mildly hyperhomocysteinemia is an independent risk 
factor for cardiovascular diseases (2). 
MTHFR represents one of the key enzymes in homocysteine 
metabolism, involved in remethylation pathway: the conver-
sion of homocysteine to methionine, using the methyl donor 
provided by the reduction of 5,10-methylene-tetrahydrofolate 
to 5-methyl-tetrahydrofolate by this enzyme. The intracellular 
concentration of homocysteine is maintained at low level by 
remethylation (requiring folate and B12 vitamin as co-factors) 
and transsulfuration reactions (requiring B6 vitamin as co-
factor). The remethylation pathway contributes predominantly 
to maintenance of the normal fasting homocysteine level 
whereas the transsulfuration maintains especially the post-
prandial concentration (5). 
The interrelations between homocysteine, MTHFR poly-
morphisms, vitamins B and folate deficiencies in cardiometa-
bolic diseases are complex. MTHFR polymorphisms result 
in hyperhomocysteinemia especially when the folate level is 
low. A recent American study, the third National Health and 
Nutrition Examination Survey (NHANES III), showed a sig-
nificant association between low serum folate and increased 
homocysteine levels in cases with MTHFR C677T genotype 
as well as the significant decreasing of homocysteinemia 
concentration by moderate daily folic acid intake. The authors 
showed the reduction of the impact of MTHFR 677C->T on 
homocysteine levels by moderate administration of folic acid 
(6). However, some authors showed an independent effect 
of MTHFR polymorphisms in atherothrombosis and a weak 
correlation between folate level and homocysteinemia (7). A 
recent French study showed that 677TT genotype is associated 
with elevated homocysteine plasma concentration in men, 
but not in women (5). Some authors showed that not only 
homozygosity for MTHFR C677T, but also the compound 
heterozygosity for C677T/A1298C may result in mild hyper-
homocysteinemia (8).
MTHFR IN METABOLIC SYNDROME
The metabolic syndrome is a cluster of factors accumulated 
in one individual, diagnosed in the presence of at least 3 of 
the following anthropometric and cardiometabolic risks: waist 
circumference more than 102 cm in men and more than 88 
cm in women, blood pressure>= 130/85, triglyceride level 
more than 150 mg/dl., HDL-cholesterol<= 40 in men, <=50 
in women, fasting glucose>= 110 mg/dl. (according to NCEP-
ATP III guidelines) (9). A recent study showed that patients 
with homozygous MTHFR genotype for T allele are at higher 
risk for insulin resistance with increasing central adiposity, 
which is independent of age, gender, body mass index, or 
metabolic syndrome diagnosis (10). 
Several studies showed an association between hyperten-
sion, hyperhomocysteinemia and  C677T MTHFR polymor-
phism. It was suggested that this genetic defect could be a 
factor explaining the increased cardiovascular risk for hy-
pertensive patients by elevated homocysteinemia. However, 
a direct association between C677T MTHFR polymorphism 
and hypertension could not been confirmed, indicating that 
other factors modulate the association between hyperhomo-
cysteinemia and essential hypertension (11).
MTHFR IN DIABETES MELLITUS
During the last decades, several studies have shown that there 
may be a link between elevated concentrations of plasma 
homocysteine and insulin resistance (12). High levels of 
homocysteinemia and a positive association with microalbu-
minuria were identified in patients with type 2 diabetes mel-
litus (13). Studies in rats showed that insulin resistance was 
associated with hyperhomocysteinemia and changes involving 
the enzymes of homocysteine metabolism; a stimulation of 
insulin-induced elimination of methionine was proposed as a 
possible explanation of this association (14). Other study failed 
to demonstrate a significant correlation between increased 
levels of homocysteine and type 1 diabetes mellitus; no sig-
nificant differences were found in homocysteinemia related to 
the metabolic control of diabetes (based on glycohemoglobin 
values) (15). Some authors showed insulin as an independent 
and significant factor for the variance of homocysteine level, 
especially in young obese patients (16). 
A recent study aimed to determine whether MTHFR C677T 
and methionine synthase reductase MTRR polymorphisms 
could be considered risk factors for early microvascular disease 
in adolescents with type 1 diabetes; the authors concluded that 
survival without retinopathy was reduced in cases with com-
bined MTHFR 677TT and MTRR 66GG genotype. They also 
showed that homozygosity for MTHFR 677 TT was related to 
earlier onset of retinopathy (17).
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MTHFR IN OBESITY
Obesity as well as overweight was associated with hyperho-
mocysteinemia; some studies showed a significant association 
between C677T polymorphism and obesity/overweight. How-
ever, a study published in 2008 (18), based on 3 longitudinal 
studies, The British Women’s Heart and Health Study, the 
Avon Longitudinal Study of Parents and Children and the 
Copenhagen City Heart Study, failed to demonstrate a signifi-
cant association between this genetic defect and obesity and 
showed that the initial positive correlation with homozygosity 
for MTHFR 677TT was a chance finding (19).
MTHFR IN CARDIOVASCULAR DISEASES
Hyperhomocysteinemia is considered an independent car-
diovascular risk factor; several studies showed that MTHFR 
C677T genotype is positively associated with arterial and ve-
nous thrombotic disease (20,21). On the other hand, MTHFR 
C677T polymorphism was not significantly associated with 
cardiovascular diseases (22,23) or venous thrombosis (24). 
The second common mutation of MTHFR gene was described 
in 1998 and consists of an A to C transition at nucleotide 1298 
(A1298C) leading to a glutamate to alanine substitution in the 
MTHFR protein with a decrease in MTHFR activity, especially 
in homozygous. 
THERAPY WITH B VITAMINS
There are controversies regarding the benefit of vitamins B 
and folate administration in patients with MTHFR polymor-
phisms and hyperhomocysteinemia; most of the studies show 
a decrease in homocysteine levels but not in cardiovascular 
events (2,7,25,26). Recently was shown that routine screen-
ing and therapy of hyperhomocysteinemia with folic acid 
and vitamins B is not recommended; furthermore, a causal 
relationship between increased levels of homocysteine and 
cardiovascular diseases was not confirmed by randomised 
controlled trials (27,28). A future direction regarding folate 
therapy could be based on the understanding of (i) caveolae/
caveosome-mediated potocytosis of folate (29) and (ii) nitric 
oxide metabolism (30). 
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